drugset / Trial / NCT03090009

Microbiome Shift in Peri-mucositis by Anti-inflammatory Drugs

NCT03090009

Phase 0 Unknown 100 enrolled Polak David
RandomizedParallel-groupDouble-blindDiagnostic

Summary

Dental implants are often used to replace missing teeth. In fact, in the US over 700,000 implants are places every year and over 2 million implants are places world wide. Peri-implant mucositis in an inflammatory condition affecting dental implants and is recognized as a risk factor for peri-implantitis (a condition affecting the bone around implants and eventually leading to implant loss). The prevalence of Peri-implant Mucositis has been reported in the literature to range from 50-90% whereas the prevalence of Peri-implantitis has been reported as high as 20%. it is commonly believed that a dysbiotic microbiome is the primary cause for these conditions. The inflammatory burden around diseased implants creates a high-protein environment which is necessary for the survival of pathogenic bacteria. It is logical, therefore, that reducing inflammation by Non Steroidal Anti-Inflammatory Drugs (NSAIDs) may create a shift in the dysbiotic microbiome to a symbiotic microbiome. The aim of the current study is to test the effects of oral NSAIDs on the peri-implant microbiome.

Timeline

Start
2017-04
Primary completion
2019-04
Completion
2020-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Flurbiprofen Small molecule 100 mg Oral

Indications